Session Details

F006 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies

Fri, Mar 19, 9:00 AM - 11:00 AM
2 CME Available Forum

DESCRIPTION

In the Management of Stevens-Johson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) there is a consensus concerning only the supportive care, topical and systemic treatments are still subject of controversies. In the first part will be presented the main clinical features and etiologies of SJS and TEN, the supportive care, the interest of the treatment by etanercept single dose and topical silver nitrate on large skin areas. In the second part there will be presented several systemic treatments and published data in the management of SJS/TEN. Based on literature review and on our experience, we propose different algorithms of management in SJS/TEN.

LEARNING OBJECTIVES

1.

Describe the main clinical features, etiology and on controversies in management options of Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

2.

Discuss the results of current therapies and of innovative therapies in SJS & TEN, compare different new approaches in topical and systemic treatments of SJS/TEN.

3.

Differentiate between different management options in SJS/TEN, present The Case For - and Against.

SCHEDULE

9:00 AM

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies.

Marius Anton Ionescu, MD, PhD, IFAAD

9:35 AM

Current management and innovative therapies in SJS & TEN.

Jose Dario Martinez, MD, IFAAD

9:55 AM

Systemic Treatments for SJS and TEN - the Case For - and Against.

Mark D.P. Davis, MD, FAAD

10:15 AM

SJS/TEN Mimics

Lindy Peta Fox, MD, FAAD

10:15 AM

IVIG for Treatment of SJS/TEN: Current Evidence.

10:35 AM

Beyond SJS/TEN: High Stakes Mimics in Oncology Patients.

Cuong Nguyen, MD, FAAD

10:55 AM

Q&A

DIRECTOR

Marius Anton Ionescu, MD, PhD, IFAAD

Marius Anton Ionescu, MD, PhD, IFAAD

Dermatology Department - University Hospital Saint Louis, Paris, France

SPEAKERS

Mark D.P. Davis, MD, FAAD

Mark D.P. Davis, MD, FAAD

Mayo Clinic

Jose Dario Martinez, MD, IFAAD

Jose Dario Martinez, MD, IFAAD

Christus Muguerza High Specialty Hospital, University of Monterrey

Cuong Nguyen, MD, FAAD

Cuong Nguyen, MD, FAAD

DISCLOSURES

Mark D.P. Davis, MD, FAAD

No financial relationships exist with ineligible companies.

Marius Anton Ionescu, MD, PhD, IFAAD

AbbVie – Speaker(Honoraria); BMS – Speaker(Honoraria); Celgene Corporation – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Speaker(No Compensation Received); Laboratoire Dermatologiques d'Uriage – Advisory Board(Honoraria); Novartis – Speaker(Honoraria); UCB – Speaker(Honoraria);

Jose Dario Martinez, MD, IFAAD

No financial relationships exist with ineligible companies.

Cuong Nguyen, MD, FAAD

No financial relationships exist with ineligible companies.